Dean Slagel - Net Worth and Insider Trading

Dean Slagel Net Worth

The estimated net worth of Dean Slagel is at least $358,043 dollars as of 2024-11-13. Dean Slagel is the Director of Cara Therapeutics Inc and owns about 1,064,338 shares of Cara Therapeutics Inc (CARA) stock worth over $358,043. Details can be seen in Dean Slagel's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Dean Slagel has not made any transactions after 2017-06-29 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Dean Slagel

To

Dean Slagel Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Dean Slagel owns 1 companies in total, including Cara Therapeutics Inc (CARA) .

Click here to see the complete history of Dean Slagel’s form 4 insider trades.

Insider Ownership Summary of Dean Slagel

Ticker Comapny Transaction Date Type of Owner
CARA Cara Therapeutics Inc 2017-06-29 director

Dean Slagel Latest Holdings Summary

Dean Slagel currently owns a total of 1 stock. Dean Slagel owns 1,064,338 shares of Cara Therapeutics Inc (CARA) as of June 29, 2017, with a value of $358,043.

Latest Holdings of Dean Slagel

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
CARA Cara Therapeutics Inc 2017-06-29 1,064,338 0.34 358,043

Holding Weightings of Dean Slagel


Dean Slagel Form 4 Trading Tracker

According to the SEC Form 4 filings, Dean Slagel has made a total of 0 transactions in Cara Therapeutics Inc (CARA) over the past 5 years. The most-recent trade in Cara Therapeutics Inc is the sale of 250,000 shares on June 29, 2017, which brought Dean Slagel around $6 Million.

Insider Trading History of Dean Slagel

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Dean Slagel Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Dean Slagel Ownership Network

Ownership Network List of Dean Slagel

No Data

Ownership Network Relation of Dean Slagel

Insider Network Chart

Dean Slagel Owned Company Details

What does Cara Therapeutics Inc do?

Who are the key executives at Cara Therapeutics Inc?

Dean Slagel is the director of Cara Therapeutics Inc. Other key executives at Cara Therapeutics Inc include Chief Medical Officer Joana Goncalves , Sec'y; Chief Compliance & G.C. Scott Terrillion , and VP-Research & Development Menzaghi Frederique Ph.d. .

Cara Therapeutics Inc (CARA) Insider Trades Summary

Over the past 18 months, Dean Slagel made no insider transaction in Cara Therapeutics Inc (CARA). Other recent insider transactions involving Cara Therapeutics Inc (CARA) include a net sale of 60,412 shares made by Christopher Posner , a net sale of 5,476 shares made by Joana Goncalves , and a net sale of 5,236 shares made by Scott Terrillion .

In summary, during the past 3 months, insiders sold 3,668 shares of Cara Therapeutics Inc (CARA) in total and bought 0 shares, with a net sale of 3,668 shares. During the past 18 months, 74,117 shares of Cara Therapeutics Inc (CARA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 74,117 shares.

Cara Therapeutics Inc (CARA)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Cara Therapeutics Inc Insider Transactions

No Available Data

Dean Slagel Mailing Address

Above is the net worth, insider trading, and ownership report for Dean Slagel. You might contact Dean Slagel via mailing address: C/o Esperante Ventures, Po Box 30127, Limhamn V7 Se-20061.